201. Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study
- Author
-
Pascale Jolliet, Pascal Caillet, Marie Gérardin, Morgane Rousselet, Caroline Victorri-Vigneau, Bodescot, Myriam, Department of Clinical Pharmacology and Addictovigilance [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), This work was funded by the French ANSM institution (AAP-2017-027) and the University Hospital of Nantes., and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
- Subjects
Male ,Pediatrics ,Time Factors ,Medical Doctors ,Databases, Factual ,Health Care Providers ,[SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior ,Social Sciences ,Rate ratio ,030226 pharmacology & pharmacy ,Geographical locations ,Cohort Studies ,0302 clinical medicine ,Epidemiology ,Medicine and Health Sciences ,Prevalence ,Psychology ,Electronic Health Records ,Hypnotics and Sedatives ,Public and Occupational Health ,030212 general & internal medicine ,Medical Personnel ,Practice Patterns, Physicians' ,education.field_of_study ,Multidisciplinary ,[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior ,musculoskeletal, neural, and ocular physiology ,Drug Information ,Drugs ,Middle Aged ,Drug Marketing ,3. Good health ,Substance abuse ,Europe ,Professions ,Prescriptions ,Research Design ,Medicine ,Prescription Drug Monitoring Programs ,Female ,France ,Confidentiality ,medicine.drug ,Cohort study ,Research Article ,Adult ,medicine.medical_specialty ,Zolpidem ,[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,Drug Research and Development ,Substance-Related Disorders ,Science ,Population ,Addiction ,Research and Analysis Methods ,Security Measures ,03 medical and health sciences ,[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,Physicians ,medicine ,Product Surveillance, Postmarketing ,Humans ,European Union ,Medical prescription ,education ,Aged ,Pharmacology ,business.industry ,Health Plan Implementation ,Biology and Life Sciences ,medicine.disease ,Health Care ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,People and Places ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Observational study ,Population Groupings ,business - Abstract
International audience; Our objective was to quantify the impact on the use of zolpidem of the obligation implemented in France in 2017 to use secure prescription pads to prescribe it. We conducted a cohort study within the French SNDS healthcare database. Patients aged over 18 years of age were considered for inclusion. The number of prevalent users and incident episodes of zolpidem use were compared before the change in law (July 1, 2016 to January 1, 2017) and after (July 1, 2017 to January 1, 2018). A prevalent user was a patient who has been reimbursed for zolpidem at least once. An incident episode of zolpidem use was defined by a first administration of zolpidem without any prior administration within the previous six months. Regarding prevalence of zolpidem users, we observed a decrease from 2.79% (CI95%:2.75-2.83) to 1.48% (1.44-1.51), with a number of patients who stopped taking it after the change in law being approximately 4.3 times higher than the number of patients who started. We observed a negative association between the post-law change period (OR = 0.52 (0.51-0.53)) and the probability of receiving zolpidem, adjusting for sex, aging, low income and chronic disease. We observed a decrease from 183 treatment episodes per 100,000 insured months on average to 79 episodes per 100,000 insured months, with an incidence rate ratio (IRR) equal to 0.43 (0.38-0.49). The use of secure prescription pads seems to have reduced the exposure of the French population to zolpidem.
- Published
- 2020
- Full Text
- View/download PDF